World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
51747
World Ranking
18228
National Ranking
3

Overview

Igor Bondarenko is affiliated with the Ministry of Internal Affairs in Romania and has an extensive publication record primarily in the field of medicine, with a focus on oncology. Their work encompasses a broad range of topics in cancer research and treatment, with a particular emphasis on lung cancer and immunotherapy.

Bondarenko's research spans several main areas and subfields, including:

  • Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Molecular Biology
  • Cancer Research

Their main topics of research include:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research

Bondarenko has published multiple papers in frequent collaboration with co-authors, including Mustafa Özgüroğlu (37 joint publications), İrfan Çiçin (20), Saadettin Kılıçkap (19), Miranda Gogishvili (17), and Petra Rietschel (16). This network highlights a consistent partnership within oncology research communities.

They have contributed to several high-impact publication venues, with the most frequent being:

  • Annals of Oncology (35 publications)
  • Journal of Clinical Oncology (24 publications)
  • Journal of Thoracic Oncology (17 publications)
  • Cancer Research (11 publications)
  • Clinical Cancer Research (7 publications)

Selected recent papers authored by Bondarenko include:

  • "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial" (2021), published in The Lancet
  • "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial" (2020), published in The Lancet Oncology
  • "Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study" (2023), published in The Lancet
  • "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial" (2020), published in UNC Libraries
  • "Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer" (2022), published in JAMA

Best Publications

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

    Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

    C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud

  • Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

    M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  • Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

    Ahmet Sezer;Saadettin Kilickap;Mahmut Gümüş;Igor Bondarenko

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Claus Garbe
Claus Garbe University of Tübingen
Joachim von Pawel
Joachim von Pawel The University of Texas MD Anderson Cancer Center
Caroline Robert
Caroline Robert University of Paris-Saclay
Silvia Novello
Silvia Novello University of Turin
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jifeng Feng
Jifeng Feng Nanjing Medical University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in alternative routes into healthcare or expanding your career options, there are several online degree programs worth considering. For nurses who want to move into leadership, research, or advanced clinical roles, pursuing dnp programs online can offer a flexible pathway to the highest level of nursing practice.

Those looking for a quicker entry into the nursing field could consider fast lpn program options. These allow students to qualify as Licensed Practical Nurses in less time, providing a valuable gateway into healthcare careers.

If your passion lies in mental health, the fastest psychiatric nurse practitioner program options online can help you specialize and serve this critical area while balancing other commitments.

For those more interested in healthcare leadership and system management, exploring the healthcare administration degrees can open doors to roles in hospital administration and health policy. Online education provides flexibility and affordability, making these career transitions more accessible than ever.

Best Scientists Citing Igor Bondarenko

Trending Scientists